Insider Selling: Tcr2 Therapeutics Inc (NASDAQ:TCRR) Major Shareholder Sells 7,743 Shares of Stock

Share on StockTwits

Tcr2 Therapeutics Inc (NASDAQ:TCRR) major shareholder Morana Jovan-Embiricos sold 7,743 shares of Tcr2 Therapeutics stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $17.65, for a total transaction of $136,663.95. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Morana Jovan-Embiricos also recently made the following trade(s):

  • On Monday, December 9th, Morana Jovan-Embiricos sold 139,989 shares of Tcr2 Therapeutics stock. The stock was sold at an average price of $17.65, for a total transaction of $2,470,805.85.
  • On Tuesday, October 22nd, Morana Jovan-Embiricos sold 3,888 shares of Tcr2 Therapeutics stock. The stock was sold at an average price of $13.42, for a total transaction of $52,176.96.
  • On Monday, September 23rd, Morana Jovan-Embiricos sold 416,321 shares of Tcr2 Therapeutics stock. The stock was sold at an average price of $17.92, for a total transaction of $7,460,472.32.

TCRR traded up $0.15 on Friday, reaching $17.00. The company had a trading volume of 16,250 shares, compared to its average volume of 97,857. Tcr2 Therapeutics Inc has a 1 year low of $10.04 and a 1 year high of $25.47. The stock has a market capitalization of $404.97 million and a PE ratio of -0.17. The stock has a 50-day moving average price of $15.38 and a 200-day moving average price of $15.41.

Tcr2 Therapeutics (NASDAQ:TCRR) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.03). On average, equities analysts expect that Tcr2 Therapeutics Inc will post -5.1 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Barclays PLC lifted its position in Tcr2 Therapeutics by 402.1% in the third quarter. Barclays PLC now owns 5,885 shares of the company’s stock valued at $89,000 after acquiring an additional 4,713 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in Tcr2 Therapeutics by 23.5% in the second quarter. Parametric Portfolio Associates LLC now owns 35,044 shares of the company’s stock valued at $501,000 after acquiring an additional 6,672 shares during the last quarter. Rhumbline Advisers purchased a new stake in Tcr2 Therapeutics in the third quarter valued at $162,000. California State Teachers Retirement System lifted its position in Tcr2 Therapeutics by 568.2% in the third quarter. California State Teachers Retirement System now owns 18,254 shares of the company’s stock valued at $274,000 after acquiring an additional 15,522 shares during the last quarter. Finally, EcoR1 Capital LLC purchased a new stake in Tcr2 Therapeutics in the second quarter valued at $231,000. 42.15% of the stock is owned by hedge funds and other institutional investors.

Several equities research analysts have recently issued reports on TCRR shares. ValuEngine cut shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. HC Wainwright reaffirmed a “buy” rating and set a $19.00 price objective on shares of Tcr2 Therapeutics in a research report on Wednesday. Finally, Zacks Investment Research cut shares of Tcr2 Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Tcr2 Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.00.

Tcr2 Therapeutics Company Profile

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.

Recommended Story: Balanced Fund

Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Clean Yield Group Lowers Stock Holdings in Quest Diagnostics Inc
Clean Yield Group Lowers Stock Holdings in Quest Diagnostics Inc
Clean Yield Group Decreases Stock Position in General Electric
Clean Yield Group Decreases Stock Position in General Electric
Clean Yield Group Grows Stock Holdings in iShares Core S&P Mid-Cap ETF
Clean Yield Group Grows Stock Holdings in iShares Core S&P Mid-Cap ETF
iShares Agency Bond ETF  Shares Bought by Clean Yield Group
iShares Agency Bond ETF Shares Bought by Clean Yield Group
Clean Yield Group Has $452,000 Position in First Solar, Inc.
Clean Yield Group Has $452,000 Position in First Solar, Inc.
Clean Yield Group Buys 2,884 Shares of AFLAC Incorporated
Clean Yield Group Buys 2,884 Shares of AFLAC Incorporated


 
© 2006-2020 Zolmax.